One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Alcohol and health: time for Europe to sober up
doi : 10.1016/S2468-1253(25)00165-7
Volume 10, Issue 7, July 2025, Page 605
Etrasimod in the treatment of eosinophilic oesophagitis: a promising match?
A plasma-based multimetabolite biomarker for early detection of pancreatic cancer
Sexual health and young people living with chronic hepatitis B: adopting a treatment as prevention framework
Hypovolaemic phlebotomy and bloodless liver surgery – Authors' reply
The role of [18F]FDG and [18F]FCH PET-CT in hepatocellular carcinoma with cirrhosis
The role of [18F]FDG and [18F]FCH PET-CT in hepatocellular carcinoma with cirrhosis – Author's reply
Refining clinical success metrics in EUS-guided gastroenterostomy
India's continued response to tackling metabolic disorders and non-communicable diseases
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles
